Our top pick for
Myriad Genetics Inc is a diagnostics & research business based in the US. Myriad Genetics shares (MYGN) are listed on the NASDAQ and all prices are listed in US Dollars. Myriad Genetics employs 2,700 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$32.48|
|52-week range||$12.22 - $36.95|
|50-day moving average||$32.60|
|200-day moving average||$31.17|
|Wall St. target price||$30.13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.26|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-0.46%|
|1 month (2021-09-27)||-0.15%|
|3 months (2021-07-27)||5.22%|
|6 months (2021-04-27)||6.04%|
|1 year (2020-10-26)||127.45%|
|2 years (2019-10-25)||0.06%|
|3 years (2018-10-26)||43.94|
|5 years (2016-10-26)||66.31%|
Valuing Myriad Genetics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Myriad Genetics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Myriad Genetics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 124x. In other words, Myriad Genetics shares trade at around 124x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Myriad Genetics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4001. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Myriad Genetics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Myriad Genetics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $14.3 million.
The EBITDA is a measure of a Myriad Genetics's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$704.9 million|
|Gross profit TTM||$416.8 million|
|Return on assets TTM||-7.65%|
|Return on equity TTM||-23.51%|
|Market capitalisation||$2.5 billion|
TTM: trailing 12 months
There are currently 4.7 million Myriad Genetics shares held short by investors – that's known as Myriad Genetics's "short interest". This figure is 2.9% down from 4.9 million last month.
There are a few different ways that this level of interest in shorting Myriad Genetics shares can be evaluated.
Myriad Genetics's "short interest ratio" (SIR) is the quantity of Myriad Genetics shares currently shorted divided by the average quantity of Myriad Genetics shares traded daily (recently around 411688.54166667). Myriad Genetics's SIR currently stands at 11.52. In other words for every 100,000 Myriad Genetics shares traded daily on the market, roughly 11520 shares are currently held short.
However Myriad Genetics's short interest can also be evaluated against the total number of Myriad Genetics shares, or, against the total number of tradable Myriad Genetics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Myriad Genetics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Myriad Genetics shares in existence, roughly 60 shares are currently held short) or 0.0846% of the tradable shares (for every 100,000 tradable Myriad Genetics shares, roughly 85 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Myriad Genetics.
Find out more about how you can short Myriad Genetics stock.
We're not expecting Myriad Genetics to pay a dividend over the next 12 months.
Myriad Genetics's shares were split on a 2:1 basis on 25 March 2009. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Myriad Genetics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Myriad Genetics shares which in turn could have impacted Myriad Genetics's share price.
Over the last 12 months, Myriad Genetics's shares have ranged in value from as little as $12.22 up to $36.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Myriad Genetics's is 1.5905. This would suggest that Myriad Genetics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Myriad Genetics, Inc. , a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.